Terms: = Leukemia AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
298 results:
1. Discovery of a Meisoindigo-Derived PROTAC as the atm Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract] [Full Text] [Related]
2. Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity.
Shi P; Lin Z; Song Y; Li Z; Zeng M; Luo L; Cao Y; Zhu X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):159. PubMed ID: 38530432
[TBL] [Abstract] [Full Text] [Related]
3. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
4. A Bizarre Progression Of Chronic Lymphocytic Leukaemia Into Diffuse Large B-Cell Lymphoma.
Shakeel D; Qadir H; Baig MM; Ojla SM
J Ayub Med Coll Abbottabad; 2023; 35(3):512-514. PubMed ID: 38404107
[TBL] [Abstract] [Full Text] [Related]
5. High expression of BCat1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia].
Zhou ZY; Dai LMJ; Sha YQ; Qiu TL; Qin SC; Miao Y; Xia Y; Wu W; Tang HN; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):917-923. PubMed ID: 38185521
[No Abstract] [Full Text] [Related]
7. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
[TBL] [Abstract] [Full Text] [Related]
8. Suppression of DNMT1 combined with atm or ATR inhibitor as a therapeutic combination of acute myeloid leukemia.
Liu L; Hu X; Feng J; Lei A; Huang S; Liu X; Liu H; Luo L; Yao W
Anticancer Drugs; 2024 Mar; 35(3):251-262. PubMed ID: 38164802
[TBL] [Abstract] [Full Text] [Related]
9. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.
Navrkalova V; Plevova K; Radova L; Porc J; Pal K; Malcikova J; Pavlova S; Doubek M; Panovska A; Kotaskova J; Pospisilova S
Br J Haematol; 2024 Jan; 204(1):240-249. PubMed ID: 38062779
[TBL] [Abstract] [Full Text] [Related]
10. Long-Smoldering T-prolymphocytic leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract] [Full Text] [Related]
11. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
12. Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia.
Salmerón-Navas FJ; Barreiro-Fernández EM; Fénix-Caballero S
Farm Hosp; 2024; 48(1):9-15. PubMed ID: 37612185
[TBL] [Abstract] [Full Text] [Related]
13. Clinical characteristics, treatment options, and prognosis of myeloid sarcoma: analysis using the SEER database.
Liang J; Yang L; Yang B; Tian Y; Ren J; Yang L
Hematology; 2023 Dec; 28(1):2247898. PubMed ID: 37594298
[TBL] [Abstract] [Full Text] [Related]
14. T-Cell Prolymphocytic leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract] [Full Text] [Related]
15. Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.
Franch-Expósito S; Mehine M; Ptashkin RN; Bolton KL; Bandlamudi C; Srinivasan P; Zhang L; Goodell MA; Gedvilaite E; Menghrajani K; Sánchez-Vela P; Mandelker D; Comen E; Norton L; Benayed R; Gao T; Papaemmanuil E; Taylor B; Levine R; Offit K; Stadler Z; Berger MF; Zehir A
JCO Precis Oncol; 2023 Aug; 7():e2300070. PubMed ID: 37561983
[TBL] [Abstract] [Full Text] [Related]
16. Pinostrobin, a fingerroot compound, regulates miR-181b-5p and induces acute leukemic cell apoptosis.
Norkaew C; Subkorn P; Chatupheeraphat C; Roytrakul S; Tanyong D
Sci Rep; 2023 May; 13(1):8084. PubMed ID: 37208425
[TBL] [Abstract] [Full Text] [Related]
17. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Thompson PA; Keating MJ; Ferrajoli A; Jain N; Peterson CB; Garg N; Wang SA; Jorgensen JL; Kadia TM; Bose P; Pemmaraju N; Short NJ; Wierda WG
Leukemia; 2023 Jul; 37(7):1444-1453. PubMed ID: 37138019
[TBL] [Abstract] [Full Text] [Related]
18. Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (atc) stem cell activity.
Zhu X; Zhao L; Doolittle WKL; Cheng SY
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36939877
[TBL] [Abstract] [Full Text] [Related]
19. atm inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract] [Full Text] [Related]
20. Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on atm-γH2AX-MDC1.
Zeng F; Peng Y; Qin Y; Wang J; Jiang G; Feng W; Yuan Y
Cell Commun Signal; 2022 Dec; 20(1):199. PubMed ID: 36575478
[TBL] [Abstract] [Full Text] [Related]
[Next]
